{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.06","upperLimit":"0.06","value":"0.06"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"0.03","value":"0.03"},{"groupId":"OG002","lowerLimit":"0.03","upperLimit":"0.04","value":"0.036"},{"groupId":"OG003","lowerLimit":"0.03","upperLimit":"0.04","value":"0.033"},{"groupId":"OG004","lowerLimit":"0.02","upperLimit":"0.09","value":"0.032"},{"groupId":"OG005","lowerLimit":"0.02","upperLimit":"0.04","value":"0.032"},{"groupId":"OG006","lowerLimit":"0.02","upperLimit":"0.03","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG007","lowerLimit":"13.96","upperLimit":"14.88","value":"14.010"},{"groupId":"OG008","lowerLimit":"13.98","upperLimit":"14.08","value":"14.058"},{"groupId":"OG009","lowerLimit":"14.00","upperLimit":"14.19","value":"14.083"},{"groupId":"OG010","lowerLimit":"13.98","upperLimit":"13.98","value":"13.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.04","upperLimit":"0.04","value":"0.04"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"0.03","value":"0.03"},{"groupId":"OG002","lowerLimit":"0.04","upperLimit":"0.04","value":"0.04"},{"groupId":"OG003","lowerLimit":"0.03","upperLimit":"0.03","value":"0.030"},{"groupId":"OG004","lowerLimit":"0.02","upperLimit":"0.05","value":"0.036"},{"groupId":"OG005","lowerLimit":"0.03","upperLimit":"0.11","value":"0.042"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG008","lowerLimit":"14.02","upperLimit":"14.02","value":"14.02"},{"groupId":"OG009","lowerLimit":"13.98","upperLimit":"13.98","value":"13.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"}],"units":"Participants"}],"description":"The Tmax of conjugated enapotamab vedotin for dose-escalation part is reported.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"OG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"OG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"OG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"OG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all participants who were exposed to at least 1 dose of enapotamab vedotin and who had at least 1 postdose PK measurement. 'Number analyzed' denotes the number of participants evaluated for the specified time point.","reportingStatus":"POSTED","timeFrame":"For 1Q3W dosing regimen: Predose, EOI, and 2 and 5 hours after EOI on Day 1 of Cycles 1 and 3; For 3Q4W dosing regimen: Predose, EOI, and 2 and 5 hours after EOI on Day 15 of Cycles 1 and 3","title":"Time of Maximum Plasma Concentration (Tmax) of Conjugated Enapotamab Vedotin for Dose-escalation Part","type":"SECONDARY","unitOfMeasure":"Day"}